Items where authors include "Rossi, A.B."

Article

Cork, M. orcid.org/0000-0003-4428-2428, Danby, S., Rossi, A.B. et al. (1 more author) (2024) Dupilumab treatment in pediatric patients aged 6–11 years with severe atopic dermatitis whose disease Is not adequately controlled: a review. Drug Design, Development and Therapy, 18. pp. 277-289. ISSN 1177-8881

Siegfried, E.C., Cork, M.J., Katoh, N. et al. (6 more authors) (2023) Dupilumab provides clinically meaningful responses in children aged 6–11 years with severe atopic dermatitis: post hoc analysis results from a phase III trial. American Journal of Clinical Dermatology, 24 (5). pp. 787-798. ISSN 1175-0561

Flohr, C. orcid.org/0000-0003-4884-6286, Irvine, A.D. orcid.org/0000-0002-9048-2044, Cork, M.J. orcid.org/0000-0003-4428-2428 et al. (6 more authors) (2023) Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6–11 years with severe atopic dermatitis. British Journal of Dermatology, 189 (2). pp. 238-240. ISSN 0007-0963

Beck, L.A., Cork, M.J. orcid.org/0000-0003-4428-2428, Amagai, M. et al. (4 more authors) (2022) Type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis. JID Innovations, 2 (5). 100131. ISSN 2667-0267

Simpson, E.L., Paller, A.S., Siegfried, E.C. et al. (10 more authors) (2021) Dupilumab demonstrates rapid and consistent improvement in extent and signs of atopic dermatitis across all anatomical regions in pediatric patients 6 years of age and older. Dermatology and Therapy, 11. pp. 1643-1656. ISSN 2193-8210

Silverberg, J.I., Simpson, E.L., Guttman-Yassky, E. et al. (15 more authors) (2021) Dupilumab significantly modulates pain and discomfort in patients with atopic dermatitis : a post hoc analysis of 5 randomized clinical trials. Dermatitis, 32 (1S). S81-S91. ISSN 1710-3568